Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Urolithiasis
Published in: Urolithiasis 2/2015

01-04-2015 | Original Paper

Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria

Authors: Klara Klimesova, Jonathan M. Whittamore, Marguerite Hatch

Published in: Urolithiasis | Issue 2/2015

Login to get access

Abstract

Hyperoxaluria significantly increases the risk of calcium oxalate kidney stone formation. Since several bacteria have been shown to metabolize oxalate in vitro, including probiotic bifidobacteria, we focused on the efficiency and possible mechanisms by which bifidobacteria can influence oxalate handling in vivo, especially in the intestines, and compared these results with the reported effects of Oxalobacter formigenes. Bifidobacterium animalis subsp. lactis DSM 10140 and B. adolescentis ATCC 15703 were administered to wild-type (WT) mice and to mice deficient in the hepatic enzyme alanine-glyoxylate aminotransferase (Agxt −/− , a mouse model of Primary Hyperoxaluria) that were fed an oxalate-supplemented diet. The administration of B. animalis subsp. lactis led to a significant decrease in urinary oxalate excretion in WT and Agxt −/− mice when compared to treatment with B. adolescentis. Detection of B. animalis subsp. lactis in feces revealed that 3 weeks after oral gavage with the bacteria 64 % of WT mice, but only 37 % of Agxt −/− mice were colonized. Examining intestinal oxalate fluxes showed there were no significant changes to net oxalate secretion in colonized animals and were therefore not associated with the changes in urinary oxalate excretion. These results indicate that colonization with B. animalis subsp. lactis decreased urinary oxalate excretion by degrading dietary oxalate thus limiting its absorption across the intestine but it did not promote enteric oxalate excretion as reported for O. formigenes. Preventive or therapeutic administration of B. animalis subsp. lactis appears to have some potential to beneficially influence dietary hyperoxaluria in mice.
Literature
1.
Weinman EJ, Frankfurt SJ, Ince A, Sansom S (1978) Renal tubular transport of organic acids. Studies with oxalate and para-aminohippurate in the rat. J Clin Investig 61(3):801–806CrossRefPubMedCentralPubMed
2.
Voss S, Hesse A, Zimmermann DJ, Sauerbruch T, von Unruh GE (2006) Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13) C2] oxalate absorption test. J Urol 175(5):1711–1715CrossRefPubMed
3.
Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America P (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165CrossRefPubMedCentralPubMed
4.
Danpure CJ (2005) Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am J Nephrol 25(3):303–310CrossRefPubMed
5.
Magwira CA, Kullin B, Lewandowski S, Rodgers A, Reid SJ, Abratt VR (2012) Diversity of faecal oxalate-degrading bacteria in black and white South African study groups: insights into understanding the rarity of urolithiasis in the black group. J Appl Microbiol 113(2):418–428CrossRefPubMed
6.
Mikami K, Akakura K, Takei K, Ueda T, Mizoguchi K, Noda M, Miyake M, Ito H (2003) Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation. Int J Urol 10(6):293–296CrossRefPubMed
7.
Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB (1999) Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10(Suppl 14):S334–S340PubMed
8.
Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141(1):1–7CrossRefPubMed
9.
Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS (2002) Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 68(8):3841–3847CrossRefPubMedCentralPubMed
10.
Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW (2006) Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 69(4):691–698CrossRefPubMed
11.
Hatch M, Freel RW (2013) A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. Urolithiasis 41(5):379–384CrossRefPubMed
12.
Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW (2011) Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liv Physiol 300(3):G461–G469CrossRef
13.
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H (2006) Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 70(7):1305–1311CrossRefPubMed
14.
Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D (2011) Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26(11):3609–3615CrossRefPubMed
15.
Lewandowski S, Rodgers AL, Laube N, von Unruh G, Zimmermann D, Hesse A (2005) Oxalate and its handling in a low stone risk vs a stone-prone population group. World J Urol 23(5):330–333CrossRefPubMed
16.
17.
Federici F, Vitali B, Gotti R, Pasca MR, Gobbi S, Peck AB, Brigidi P (2004) Characterization and heterologous expression of the oxalyl coenzyme A decarboxylase gene from Bifidobacterium lactis. Appl Environ Microbiol 70(9):5066–5073CrossRefPubMedCentralPubMed
18.
Turroni S, Bendazzoli C, Dipalo SC, Candela M, Vitali B, Gotti R, Brigidi P (2010) Oxalate-degrading activity in Bifidobacterium animalis subsp. lactis: impact of acidic conditions on the transcriptional levels of the oxalyl coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes. Appl Environ Microbiol 76(16):5609–5620CrossRefPubMedCentralPubMed
19.
Turroni S, Vitali B, Bendazzoli C, Candela M, Gotti R, Federici F, Pirovano F, Brigidi P (2007) Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus. J Appl Microbiol 103(5):1600–1609CrossRefPubMed
20.
Kwak C, Jeong BC, Ku JH, Kim HH, Lee JJ, Huh CS, Baek YJ, Lee SE (2006) Prevention of nephrolithiasis by Lactobacillus in stone-forming rats: a preliminary study. Urol Res 34(4):265–270CrossRefPubMed
21.
Murphy C, Murphy S, O’Brien F, O’Donoghue M, Boileau T, Sunvold G, Reinhart G, Kiely B, Shanahan F, O’Mahony L (2009) Metabolic activity of probiotics-oxalate degradation. Vet Microbiol 136(1–2):100–107CrossRefPubMed
22.
Heuvelin E, Lebreton C, Bichara M, Cerf-Bensussan N, Heyman M (2010) A Bifidobacterium probiotic strain and its soluble factors alleviate chloride secretion by human intestinal epithelial cells. J Nutr 140(1):7–11CrossRefPubMed
23.
Raheja G, Singh V, Ma K, Boumendjel R, Borthakur A, Gill RK, Saksena S, Alrefai WA, Ramaswamy K, Dudeja PK (2010) Lactobacillus acidophilus stimulates the expression of SLC26A3 via a transcriptional mechanism. Am J Physiol Gastrointest Liver Physiol 298(3):G395–G401CrossRefPubMedCentralPubMed
24.
Xu H, Zisman AL, Coe FL, Worcester EM (2013) Kidney stones: an update on current pharmacological management and future directions. Expert Opin Pharmacother 14(4):435–447CrossRefPubMedCentralPubMed
25.
Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C (2001) Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 60(3):1097–1105CrossRefPubMed
26.
27.
Al-Wahsh I, Wu Y, Liebman M (2012) Acute probiotic ingestion reduces gastrointestinal oxalate absorption in healthy subjects. Urol Res 40(3):191–196CrossRefPubMed
28.
Ferraz RR, Marques NC, Froeder L, Menon VB, Siliano PR, Baxmann AC, Heilberg IP (2009) Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients. Urol Res 37(2):95–100CrossRefPubMed
29.
Goldfarb DS, Modersitzki F, Asplin JR (2007) A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2(4):745–749CrossRefPubMed
30.
Lieske JC, Goldfarb DS, De Simone C, Regnier C (2005) Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 68(3):1244–1249CrossRefPubMed
31.
Lieske JC, Tremaine WJ, De Simone C, O’Connor HM, Li X, Bergstralh EJ, Goldfarb DS (2010) Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int 78(11):1178–1185CrossRefPubMedCentralPubMed
32.
Okombo J, Liebman M (2010) Probiotic-induced reduction of gastrointestinal oxalate absorption in healthy subjects. Urol Res 38(3):169–178CrossRefPubMed
33.
Salido EC, Li XM, Lu Y, Wang X, Santana A, Roy-Chowdhury N, Torres A, Shapiro LJ, Roy-Chowdhury J (2006) Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci USA 103(48):18249–18254CrossRefPubMedCentralPubMed
34.
Heinegard D, Tiderstrom G (1973) Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta 43(3):305–310CrossRefPubMed
35.
Junick J, Blaut M (2012) Quantification of human fecal bifidobacterium species by use of quantitative real-time PCR analysis targeting the groEL gene. Appl Environ Microbiol 78(8):2613–2622CrossRefPubMedCentralPubMed
36.
Freel RW, Hatch M, Green M, Soleimani M (2006) Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. Am J Physiol Gastrointest Liver Physiol 290(4):G719–G728CrossRefPubMed
37.
38.
Conway PL (1996) Selection criteria for probiotic microorganisms. Asia Pac J Clin Nutr 5(1):10–14PubMed
39.
Lange JN, Wood KD, Wong H, Otto R, Mufarrij PW, Knight J, Akpinar H, Holmes RP, Assimos DG (2012) Sensitivity of human strains of Oxalobacter formigenes to commonly prescribed antibiotics. Urology 79(6):1286–1289CrossRefPubMedCentralPubMed
40.
Mittal RD, Kumar R, Bid HK, Mittal B (2005) Effect of antibiotics on Oxalobacter formigenes colonization of human gastrointestinal tract. J Endourol 19(1):102–106CrossRefPubMed
Metadata
Title
Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria
Authors
Klara Klimesova
Jonathan M. Whittamore
Marguerite Hatch
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Urolithiasis / Issue 2/2015
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-014-0728-2

Other articles of this Issue 2/2015

Urolithiasis 2/2015 Go to the issue

Original Paper

New potential solutions for the chemolysis of urinary phosphate calculi determined by an in vitro study

Original Paper

Changes in stone composition over two decades: evaluation of over 10,000 stone analyses

Letter to the Editor

Anecdotes of lithogenesis and atherogenesis conversely liable for cardiac dysfunction and kidney stone formation

Original Paper

Acceptance of mixed scientific and clinical activities in a sub-speciality urology meeting

Original Paper

Retro-renal colon: role in percutaneous access

Original Paper

Aqueous extract of Costus arabicus inhibits calcium oxalate crystal growth and adhesion to renal epithelial cells